A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering patient recruitment and retention services. Majority of these players possess vast service portfolios...